AUS
NZ
UK
CA
USA
IND
Highlights:
- Neurotech International (ASX:NTI) was denied orphan drug status by the FDA for NTI164, citing concerns over the rarity of its target conditions.
- The FDA questioned the distinction between PANDAS and PANS, and the prevalence data provided by Neurotech.
- Neurotech has 12 months to submit additional evidence and clarify its position with the FDA.
Neurotech International Ltd (ASX:NTI) has informed shareholders of a recent decision from the U.S. Food and Drug Administration (FDA) regarding its product, NTI164. The FDA has declined to grant orphan drug status to NTI164, citing that the targeted conditions do not meet the criteria for rarity.
Orphan drug status is a designation by the FDA that can be given to medications aimed at treating rare diseases. The status provides benefits such as tax credits for clinical trials, reduced regulatory fees, and the potential for seven years of market exclusivity. However, the FDA’s decision centers on Neurotech’s two target conditions: Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
FDA’s Assessment of PANDAS and PANS
The FDA did not dispute the existence of PANDAS, a condition in which children develop obsessive-compulsive disorder (OCD) symptoms after a strep infection. PANDAS is believed to be an autoimmune disorder, with natural antibodies produced to combat the infection potentially crossing the blood-brain barrier, triggering or exacerbating OCD symptoms.
However, the FDA raised concerns about PANS, suggesting that it may not be sufficiently distinct from PANDAS to warrant separate classification. The agency questioned whether there is enough evidence to consider PANS a rare, standalone condition. This poses a challenge for Neurotech, as the company had hoped to qualify for orphan drug status based on treating two rare conditions, rather than just one.
Prevalence Data Under Scrutiny
The FDA also questioned the prevalence data provided by Neurotech, which suggests that PANDAS affects 1 in 200 children in the United States. This estimate forms a key part of the company's argument for orphan drug designation. The FDA’s concerns indicate that the agency may not be fully convinced that the condition qualifies as rare under its standards.
As a result of these issues, Neurotech now has 12 months to respond to the FDA with further supporting evidence. The company has stated that it is currently assessing its next steps.
Key Challenges Ahead
For Neurotech, the denial of orphan drug status presents a significant hurdle. Without the designation, the company may face additional costs and complexities in advancing NTI164 through clinical trials and regulatory approval processes. Orphan drug status would have provided substantial financial and regulatory advantages, and the loss of these benefits could slow the development of NTI164.
Despite the setback, Neurotech remains in dialogue with the FDA and has the opportunity to provide additional data that could strengthen its case. The company’s ability to address the FDA’s concerns will likely determine the future trajectory of its product development.
